| Catalog No. | HS856086 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Humanized |
|---|
| Isotype | VH-VH'-VH |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A, IL17F, Interleukin-17F, IL-17F, Cytokine ML-1, ALB, Albumin |
|---|
| Concentration | 1.42mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | Q16552 & Q96PD4 & P02768 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 30mM Histidine ,pH5.8,10% sucrose,0.02% Tween80 |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -1426°C. |
|---|
| Alternate Names | Bispecific,Trivalent,M-1095,MSB-0010841,CAS:1414386-05-2 |
|---|
| Background | Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
